Fusion Antibodies (LON:FAB) Trading 2% Higher – Here’s Why

Fusion Antibodies plc (LON:FAB) rose 2% during mid-day trading on Tuesday . The stock traded as high as GBX 11.40 and last traded at GBX 10.71. Approximately 159,643 shares were traded during trading, a decline of 60% from the average session volume of 402,811 shares. The stock had previously closed at GBX 10.50.

Fusion Antibodies Stock Up 2.0%

The company has a debt-to-equity ratio of 92.42, a quick ratio of 2.36 and a current ratio of 1.80. The firm has a market capitalization of £13.40 million, a price-to-earnings ratio of -7.14 and a beta of 1.22. The firm has a fifty day moving average price of GBX 10.92 and a 200 day moving average price of GBX 12.52.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.